Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Research Article Volume 7 Issue 5

Role of Oxidized Dextran in Prevention and Control of Viral Pneumonia and Pulmonary Fibrosis

AV Troitsky1, LA Cherdantseva3, TN Bystrova1, EG Novikova1,2*, HU Ukah1, OV Grishin1 and EA Lyadov4

1Federal Medical Research Centre of Fundamental and Translational Medicine, Novosibirsk, Russia
2Regional Medical and Diagnostic Centre Ltd., Novosibirsk, Russia
3Novosibirsk Research Institute of Traumatology and Orthopedics n.a. Ya.L. Tsivyan, Novosibirsk, Russia
4St. Petersburg Tuberculosis Sanatorium “Pinery”, Saint Petersburg, Russia

*Corresponding Author: EG Novikova, Federal Medical Research Centre of Fundamental and Translational Medicine, Novosibirsk, Russia.

Received: April 05, 2023; Published: April 24, 2023


Rationale for the Study: The relevance of the study is due to the large number of fibrous complications in viral interstitial pneumonia in COVID-19 patients in where …. Pulmonary fibrosis develops most often.

Objective of the Study: Title of the study to evaluate Role of Oxidized Dextran In Prevention and Control of Viral Pneumonia and Pulmonary Fibrosis

Specifically the therapeutic efficacy of inhalation administration of 2% oxidized dextran solution in an in vivo model that mimics interstitial pneumonia in COVID-19.

Materials and Methods: The studies were performed on mice of the ACR line. And interstitial pneumonia in mice was caused by intranasal administration of the lipopolysaccharide Escherichia coli (LPS)." After intranasal administration of LPS to mice and legalization of a 2% solution of oxidized dextran and a control solution (physiological solution), they were carried out using an ultrasonic inhaler. A day later, the animals were slaughtered and prepared standard histological sections of lung tissue, followed by morphometric evaluation of the results.

Results with Data: inhalation administration of a 2% solution of oxidized dextran can almost 2 times reduce all morphological manifestations of LPS induced pneumonia by morphometric indicators: histe density of vessels with signs of hemocirculatory disorders, numerical density of thrombosed vessels, percentage of thrombosed vessels, volumetric density of hemorrhages, volumetric density of hemorrhages atelectasis, and volumetric density of cellular inflammatory infiltrate).

Conclusion: And the administration of oxidized dextran solutions may be a very promising method of preventing pulmonary fibrosis in COVID-19.

 Keywords: Oxidized Dextran; Pneumonia; Pulmonary Fibrosis; Prevention and Control; COVID 19


  1. Myall KJ., et al. “Persistent Post–COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment”. Annals of the American Thoracic Society 5 (2021): 799-806.
  2. Shkurupy VA., et al. “Structural changes in the lungs and liver of mice with experimental tuberculosis treated with liposome-encapsulated dextrazide”. Bulletin of Experimental Biology and Medicine5 (2020): 654-657.
  3. Shkurupy VA., et al. “Efficacy of inhalations of antituberculous compositions with different length of experimental therapy course in mice”. Bulletin of Experimental Biology and Medicine6 (2020): 743-747.
  4. Tale S., et al. “Post COVID-19 pneumonia pulmonary fibrosis”. QJM11 (2020): 837-838.
  5. Udwadia Z F., et al. “Post-COVID lung fibrosis: The tsunami that will follow the earthquake”. Lung India 38 (2021): S41-S47.
  6. Vasarmidi E., et al. “Pulmonary fibrosis in the aftermath of the COVID-19 era (Review)”. Experimental and Therapeutic Medicine 3 (2020): 2557-2560.
  7. Zhang Y., et al. “Traditional Chinese medicine combined with pulmonary drug delivery system and idiopathic pulmonary fibrosis: Rationale and therapeutic potential”. Biomedicine and Pharmacotherapy 133 (2021): 111072.
  8. Zheng Y., et al. “Meta-analysis of chest CT features of patients with COVID-19 pneumonia”. Journal of Medical Virology1 (2021): 241-249.
  9. Бровко МЮ., et al. “Новые подходы к лечению фиброзирующих интерстициальных заболеваний легких”. Клиническая фармакология и терапия1 (2020): 61-66. [Brovko M.Yu., Akulkina L.A., Sholomova V.I., Sholomova V.I., Novikov P.I., Yanakaeva A.Sh., Moiseev S.V. New approaches to the treatment of fibrosing interstitial lung diseases”. Clinical Pharmacology and Therapy 29.1 (2020): 61-66.
  10. Временные методические рекомендации МЗ РФ. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 11. 07.05.2021 [Temporary methodological recommendations. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Ministry of Health of the Russian Federation. Version 11. 07.05.2021.
  11. Кательникова АЕ., et al. “Экспериментальные модели острого бронхита на животных”. Лабораторные животные для научных исследований 1 (2019): 127-151. [Katelnikova A. E., Kryshen K. L., Makarova M N and Makarov V G. “Experimental models of acute bronchitis in animals”. Laboratory Animals for Scientific Research 1 (2019): 127-151.
  12. Лонгидаза. Инструкция по применению.
  13. Некрасов АВ., et al. “Лонгидаза — современный подход в лечении заболеваний, сопровождающихся гиперплазией соединительной ткани”. Signatura 1 (2006): 43–52. [Nekrasov A.V., Ivanova A.S., Puchkova N.G. Longidase is a modern approach in the treatment of diseases accompanied by connective tissue hyperplasia. Signatura 1 (2006): 43–52.
  14. Некрасов АВ., et al. “Физико-химические принципы создания Лонгидазы”. Иммунология 2 (2006): 114-118. [Nekrasov A.V., Puchkova N.G., Karaputadze N.T. Physico-chemical principles of Longidase creation”. Immunology 27.2 (2006): 114-118.
  15. Новиков ЛН., et al. “Результаты применения Лонгидазы у больных идиопатическим фиброзирующим альвеолитом”. Доктор 6 (2011): 50-54 [Novikov L. N., Zakharova AS., et al. “Results of the use of Longidase in patients with idiopathic fibrosing alveolitis”. Doctor 6 (2011): 50-54.
  16. Патент на изобретение РФ №2728938 «Применение даларгина для производства средств лечения профилактики пневмонии», опубл. 03.08.2020, Бюл. №22 [Patent for the invention of the Russian Federation No. 2728938 "The use of dalargin for the production of drugs for the prevention of pneumonia” (2020).
  17. ВА Шкурупий. “Туберкулезный гранулематоз. Цитофизиология и адресная терапия”. Изд. РАМН, (2007): 536. [Tuberculous granulomatosis. Cytophysiology and targeted therapy/V.A. Shkurupiy. M: RAMS Publishing House, (2007): 536.
  18. Цитоморфологическсе аспекты патогенеза вирусного гриппа и его неспецифической профилактики/В. А. Шкурупий. – Новосибирск: Издательство Наука, (2019): 259. [Cytomorphological aspects of the pathogenesis of viral influenza and its nonspecific prevention] V.A. Shkurupiy. - Novosibirsk: Nauka Publishing House, (2019): 259.


Citation: EG Novikova., et al. “Role of Oxidized Dextran in Prevention and Control of Viral Pneumonia and Pulmonary Fibrosis”.Acta Scientific Medical Sciences 7.5 (2023): 164-172.


Copyright: © 2023 EG Novikova., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 30th, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue".
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US